Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
MALVERN, Pa.
Read moreMALVERN, Pa.
Read moreMONTVALE, N.J.
Read moreDemand for pharmaceutical glass packaging increasi
Read more2024 Albert B.
Read moreFirst Quarter 2024 Highlights Net income for the
Read moreAccording to a market r
Read moreIncreasingly Stringent Regulations Governing Carbo
Read moreNEW YORK, April 18, 2024 (GLOBE NEWSWIRE) —
Read moreDALLAS, April 18, 2024 (GLOBE NEWSWIRE) —
Read moreTampa, FL, April 18, 2024 (GLOBE NEWSWIRE) ̵
Read more